EP0661972A4 - Use of spiperone or spiperone derivatives as immunosuppressant agents. - Google Patents

Use of spiperone or spiperone derivatives as immunosuppressant agents.

Info

Publication number
EP0661972A4
EP0661972A4 EP19930902752 EP93902752A EP0661972A4 EP 0661972 A4 EP0661972 A4 EP 0661972A4 EP 19930902752 EP19930902752 EP 19930902752 EP 93902752 A EP93902752 A EP 93902752A EP 0661972 A4 EP0661972 A4 EP 0661972A4
Authority
EP
European Patent Office
Prior art keywords
spiperone
derivatives
immunosuppressant agents
immunosuppressant
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19930902752
Other languages
German (de)
French (fr)
Other versions
EP0661972A1 (en
Inventor
Richard J Sharpe
Kenneth A Arndt
Stephen J Galli
Peter C Meltzer
Raj K Razdan
Howard P Sard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/815,283 external-priority patent/US5290783A/en
Priority claimed from US07/831,429 external-priority patent/US5244902A/en
Priority claimed from US07/893,536 external-priority patent/US5703088A/en
Priority claimed from US07/893,534 external-priority patent/US5574041A/en
Application filed by Beth Israel Hospital Association filed Critical Beth Israel Hospital Association
Publication of EP0661972A4 publication Critical patent/EP0661972A4/en
Publication of EP0661972A1 publication Critical patent/EP0661972A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
EP93902752A 1991-12-27 1992-12-23 Use of spiperone or spiperone derivatives as immunosuppressant agents Withdrawn EP0661972A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US831429 1986-02-20
US815283 1991-12-27
US07/815,283 US5290783A (en) 1990-03-16 1991-12-27 Use of spiperone derivatives as immunosuppressant agents
US07/831,429 US5244902A (en) 1989-08-21 1992-02-05 Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US893534 1992-06-04
US07/893,536 US5703088A (en) 1989-08-21 1992-06-04 Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US07/893,534 US5574041A (en) 1990-03-16 1992-06-04 Use of spiperone derivatives as immunosuppressant agents
PCT/US1992/011205 WO1993012789A1 (en) 1991-12-27 1992-12-23 Use of spiperone or spiperone derivatives as immunosuppressant agents
US893536 2001-06-28

Publications (2)

Publication Number Publication Date
EP0661972A4 true EP0661972A4 (en) 1994-10-27
EP0661972A1 EP0661972A1 (en) 1995-07-12

Family

ID=27505847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93902752A Withdrawn EP0661972A1 (en) 1991-12-27 1992-12-23 Use of spiperone or spiperone derivatives as immunosuppressant agents

Country Status (5)

Country Link
EP (1) EP0661972A1 (en)
JP (1) JPH08500326A (en)
AU (1) AU3421493A (en)
CA (1) CA2126678A1 (en)
WO (1) WO1993012789A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO1997023221A1 (en) * 1995-12-21 1997-07-03 Eli Lilly And Company Method for treating dermatitis
EP1080091A1 (en) * 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US6277991B1 (en) 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US20050191302A1 (en) * 2002-08-29 2005-09-01 University Of Southampton Treatment for liver disease
NZ538307A (en) 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
AU2007325355A1 (en) 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor
JP2020519639A (en) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Treatment of gastroparesis with triazaspiro[4.5]decanone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (en) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
WO1991013622A1 (en) * 1990-03-16 1991-09-19 Beth Israel Hospital Association Use of spiperone as an immunosuppressant and anti-inflammatory agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (en) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
WO1991013622A1 (en) * 1990-03-16 1991-09-19 Beth Israel Hospital Association Use of spiperone as an immunosuppressant and anti-inflammatory agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. CHANDRASEKAR ET AL.: "SPIPERONE METHYL AMMONIUM BROMIDE INHIBITS CUTANEOUS CONTACT HYPERSENSITIVITY IN THE MOUSE", CLINICAL RESEARCH, vol. 41, no. 3, 1993, pages 606A *
E. OKKERSE ET AL.: "IDENTIFICATION OF CRYSTALLINE DERIVATIVES OF BUTYROPHENONES BY X-RAY DIFFRACTION: ...", JOURNAL OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, vol. 54, no. 6, 1971, pages 1406 - 1419 *
R.J. SHARPE ET AL.: "INHIBITION OF CUTANEOUS CONTACT HYPERSENSITIVITY IN THE MOUSE WITH SYSTEMIC OR TOPICAL SPIPERONE: TOPICAL APPLICATION OF SPIPERONE PRODUCES LOCAL IMMUNOSUPPRESSION WITHOUT INDUCING SYSTEMIC NEUROLEPTIC EFFECTS", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 99, no. 5, November 1992 (1992-11-01), pages 594 - 600 *
S.M. MOERLEIN ET AL.: "EFFECT OF LIPOPHILICITY ON THE IN VIVO LOCALIZATION OF RADIOLABELLED SPIPERONE ANALOGUES", INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE AND BIOLOGY, vol. 12, no. 5, 1985, pages 353 - 356 *
See also references of WO9312789A1 *

Also Published As

Publication number Publication date
AU3421493A (en) 1993-07-28
WO1993012789A1 (en) 1993-07-08
JPH08500326A (en) 1996-01-16
CA2126678A1 (en) 1993-07-08
EP0661972A1 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
GR3035574T3 (en) Use of substituted benzimidazoles.
GR3030794T3 (en) Substituted thiazolidinedione derivatives.
EP0671911A4 (en) Carboxy-peptidyl derivatives as antidegenerative active agents.
HK19496A (en) Use of 1,2,2,3,3-penta-fluoropropane
EP0661972A4 (en) Use of spiperone or spiperone derivatives as immunosuppressant agents.
ZA9110018B (en) 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity.
ZA918074B (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloakanone derivatives and their use as collage/nase inhibitors.
PL309259A1 (en) Insecticidal derivatives of 5-substituted 2,4-diamine pyride
ZA929770B (en) Heterocyclic compounds and their preparation and use
ZA928742B (en) Heterocyclic derivatives.
ZA929934B (en) Heterocyclic derivatives.
EP0592903A3 (en) Use of ancrod for the preparation of drugs for the treatment of restenosis.
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
NZ243648A (en) Cyclohexane and tetrahydro-pyran derivatives, preparation and use as fungicidal agents
GR3021267T3 (en) Use of thiadiazoles as antifouling agent.
ZA923766B (en) Substituted benzothiazol derivatives,their preparation and use as herbicides
ZA929738B (en) New use of amino acid derivatives.
ZA929716B (en) Guanidine derivatives.
EP0650723A3 (en) Novel pharmaceutical use of forskolin derivatives.
IL93658A0 (en) 3-aryl-4-cyanopyrrole derivatives and their use as microbicides
IL108450A0 (en) Pyrazole derivatives, their preparation and their use as microbicides
EP0459660A3 (en) Halopropargyl compounds and the use thereof as microbicides
ZA91614B (en) Agent for use in the prevention,control or reversal of hypertension
EP0644716A4 (en) Medical uses of trioxolane and diperoxide compounds.
NZ250159A (en) Use of furan-3-carboxamides as microbicides

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980416

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990701